{"id":"cannabidiol-oral-product","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Somnolence"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Decreased appetite"},{"rate":"10-15","effect":"Elevated liver transaminases"},{"rate":"5-10","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CBD does not directly bind with high affinity to CB1 or CB2 receptors but instead acts as an allosteric modulator of these receptors and interacts with serotonin 5-HT1A receptors, vanilloid TRPV1 channels, and other ion channels. This multi-target mechanism underlies its therapeutic effects in reducing seizure frequency, anxiety, and inflammation without producing the psychoactive effects associated with THC.","oneSentence":"Cannabidiol (CBD) is a non-intoxicating cannabinoid that modulates multiple molecular targets including serotonin receptors, TRPV1 channels, and endocannabinoid signaling to produce anti-inflammatory, anxiolytic, and anticonvulsant effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:42.948Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seizures associated with Lennox-Gastaut syndrome"},{"name":"Seizures associated with Dravet syndrome"},{"name":"Seizures associated with tuberous sclerosis complex"}]},"trialDetails":[{"nctId":"NCT07233239","phase":"PHASE1","title":"A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2025-11-26","conditions":"Focal Seizures","enrollment":100},{"nctId":"NCT07459920","phase":"PHASE2","title":"Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2026-04-01","conditions":"Advanced Malignant Solid Tumor","enrollment":156},{"nctId":"NCT07462559","phase":"PHASE1","title":"KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2026-03-04","conditions":"Drug Drug Interaction","enrollment":12},{"nctId":"NCT04550377","phase":"PHASE2","title":"Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-05-26","conditions":"Post Traumatic Stress Disorder, Traumatic Brain Injury","enrollment":120},{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT06930872","phase":"PHASE1","title":"Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2025-06-06","conditions":"Drug Interaction","enrollment":29},{"nctId":"NCT05066308","phase":"PHASE2","title":"Cannabidiol for Reduction of Brain Neuroinflammation","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-01-04","conditions":"Back Pain, Depressive Symptoms","enrollment":80},{"nctId":"NCT06845124","phase":"PHASE2","title":"A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-07-22","conditions":"Alcohol Addiction, Alcoholism","enrollment":150},{"nctId":"NCT05052541","phase":"PHASE3","title":"Safety and Efficacy of Oral Cannabis in Chronic Spine Pain","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-01","conditions":"Back Pain, Neck Pain","enrollment":157},{"nctId":"NCT07359976","phase":"NA","title":"Pharmacokinetic Evaluation of a Natural CBD Extract","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-01-04","conditions":"Pharmacokinetics of CBD Extract, Oral and Topical Administrations","enrollment":20},{"nctId":"NCT04411225","phase":"PHASE3","title":"Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2022-06-01","conditions":"Early Psychosis","enrollment":120},{"nctId":"NCT05571592","phase":"PHASE2","title":"Cannabidiol as a Treatment for Social Anxiety Disorder (R61)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-01-26","conditions":"Social Anxiety Disorder","enrollment":60},{"nctId":"NCT05445804","phase":"PHASE1","title":"Oral Cannabidiol for Tobacco Cessation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-11-01","conditions":"Tobacco Use, Tobacco Smoking, Tobacco Dependence","enrollment":50},{"nctId":"NCT05644262","phase":"PHASE2","title":"Life's End Benefits of cannaBidiol and tetrahYdrocannabinol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-12-18","conditions":"Agitation, Dementia","enrollment":120},{"nctId":"NCT06615284","phase":"PHASE1","title":"A Study of Atorvo+™ in Healthy Adult Participants","status":"COMPLETED","sponsor":"Indication Bioscience LLC","startDate":"2025-01-28","conditions":"Coronary Heart Disease, Dyslipidemias","enrollment":24},{"nctId":"NCT07278505","phase":"PHASE1, PHASE2","title":"Study of Cannabidiol and Neuroimaging on Stress","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-10-28","conditions":"Early Life Adversity, Trauma, Stress","enrollment":160},{"nctId":"NCT07199218","phase":"PHASE2","title":"Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism","status":"RECRUITING","sponsor":"Bazelet Nehushtan LtD.","startDate":"2025-10-05","conditions":"Autism, Autism Spectrum Disorder","enrollment":78},{"nctId":"NCT07224932","phase":"PHASE2","title":"Tolerability and Efficacy of CBD Extract for RLS Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-19","conditions":"Restless Leg Syndrome","enrollment":60},{"nctId":"NCT04517799","phase":"PHASE2","title":"Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2020-06-01","conditions":"Autism, Autism Spectrum Disorder","enrollment":42},{"nctId":"NCT03787628","phase":"PHASE2","title":"Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-05-19","conditions":"Opioid-use Disorder","enrollment":35},{"nctId":"NCT06192589","phase":"PHASE1","title":"Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2024-02-08","conditions":"Cannabidiol, Drug Induced Liver Injury, Drug Interaction","enrollment":241},{"nctId":"NCT05269628","phase":"PHASE2","title":"Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","status":"RECRUITING","sponsor":"Tiffany J. Braley, MD, MS","startDate":"2022-03-25","conditions":"Multiple Sclerosis, Sleep, Pain","enrollment":166},{"nctId":"NCT05283382","phase":"EARLY_PHASE1","title":"Cannabidiol Effects on Learning and Anxiety","status":"RECRUITING","sponsor":"University of Connecticut","startDate":"2024-10-30","conditions":"Anxiety and Fear","enrollment":160},{"nctId":"NCT04044729","phase":"EARLY_PHASE1","title":"Mechanisms of CBD for Chronic Pain","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-03-16","conditions":"Chronic Pain","enrollment":24},{"nctId":"NCT04428203","phase":"PHASE1","title":"Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"Zin W Myint","startDate":"2020-08-03","conditions":"Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma","enrollment":21},{"nctId":"NCT06218056","phase":"PHASE2","title":"Cannabidiol for Reducing Cigarette Use","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-10-31","conditions":"Tobacco Use Disorder, Tobacco Smoking, Tobacco Dependence","enrollment":120},{"nctId":"NCT05823753","phase":"PHASE2","title":"Cannabidiol to Reduce Anxiety Reactivity","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2023-04-19","conditions":"Social Anxiety, Social Anxiety Disorder","enrollment":63},{"nctId":"NCT03679949","phase":"PHASE1","title":"Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-04-01","conditions":"Pain, Abuse, Drug","enrollment":26},{"nctId":"NCT04280289","phase":"EARLY_PHASE1","title":"CBD Cannabis Extract: Pharmacokinetic Studies","status":"COMPLETED","sponsor":"University of Mississippi, Oxford","startDate":"2021-02-01","conditions":"Epilepsy","enrollment":10},{"nctId":"NCT06692933","phase":"EARLY_PHASE1","title":"Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel","status":"RECRUITING","sponsor":"Washington State University","startDate":"2024-06-20","conditions":"Interaction","enrollment":24},{"nctId":"NCT06105138","phase":"NA","title":"Cannabidiol Effects on Blood Alcohol Level and Intoxication","status":"COMPLETED","sponsor":"Colorado State University","startDate":"2021-03-09","conditions":"Alcohol Use Disorder","enrollment":37},{"nctId":"NCT04760613","phase":"PHASE1, PHASE2","title":"CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2022-02-03","conditions":"Radiculopathy","enrollment":14},{"nctId":"NCT04603391","phase":"PHASE4","title":"Cannabidiol and CES1 Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-25","conditions":"Drug Interaction","enrollment":14},{"nctId":"NCT06393101","phase":"PHASE1","title":"The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-06-01","conditions":"Complex Regional Pain Syndrome","enrollment":52},{"nctId":"NCT03676049","phase":"","title":"Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)","status":"AVAILABLE","sponsor":"John","startDate":"","conditions":"Drug Resistant Epilepsy","enrollment":""},{"nctId":"NCT04642404","phase":"PHASE1, PHASE2","title":"CBD for Dental Pain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-03-01","conditions":"Odontalgia, Toothache","enrollment":64},{"nctId":"NCT04520685","phase":"PHASE2","title":"CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-12-15","conditions":"Autism Spectrum Disorder","enrollment":86},{"nctId":"NCT05407285","phase":"PHASE1, PHASE2","title":"A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-07-22","conditions":"Cannabis","enrollment":70},{"nctId":"NCT05143424","phase":"PHASE1","title":"Evaluation of the Interactions of Cannabidiol (CBD) With Morphine","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2021-11-04","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT05232123","phase":"EARLY_PHASE1","title":"Cannabidiol Effects on Cardiovascular System and Exercise Responses","status":"WITHDRAWN","sponsor":"Castleton University","startDate":"2023-07","conditions":"Healthy","enrollment":""},{"nctId":"NCT06286839","phase":"NA","title":"Study of Cannabidiol (CBD) in Healthy Volunteers","status":"COMPLETED","sponsor":"NextEvo Inc.","startDate":"2022-05-12","conditions":"Immune System and Related Disorders, Immune System Diseases","enrollment":26},{"nctId":"NCT03941288","phase":"PHASE2","title":"Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-09-04","conditions":"Gastroparesis, Dyspepsia","enrollment":92},{"nctId":"NCT03196934","phase":"","title":"Expanded Use of Cannabidiol Oral Solution","status":"NO_LONGER_AVAILABLE","sponsor":"MultiCare Health System Research Institute","startDate":"","conditions":"Refractory Epilepsy","enrollment":""},{"nctId":"NCT04036968","phase":"PHASE2","title":"Enhancing Medication-based Analgesia in Humans- STUDY 2","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-02-01","conditions":"Pain, Cannabis, Opioid Use","enrollment":31},{"nctId":"NCT03467113","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol","status":"COMPLETED","sponsor":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","startDate":"2018-01-19","conditions":"Dravet Syndrome, Lennox Gastaut Syndrome","enrollment":9},{"nctId":"NCT04396730","phase":"PHASE4","title":"Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2020-04-08","conditions":"Contraception","enrollment":9},{"nctId":"NCT04447846","phase":"PHASE2","title":"Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome","status":"COMPLETED","sponsor":"Anne Comi, MD","startDate":"2019-10-14","conditions":"Sturge-Weber Syndrome","enrollment":11},{"nctId":"NCT04192370","phase":"PHASE2","title":"Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-08-03","conditions":"Opioid-use Disorder","enrollment":8},{"nctId":"NCT04731779","phase":"EARLY_PHASE1","title":"Cannabidiol and Autonomic Function at Rest","status":"COMPLETED","sponsor":"Castleton University","startDate":"2021-08-30","conditions":"Healthy","enrollment":18},{"nctId":"NCT05803434","phase":"PHASE2","title":"Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy","status":"UNKNOWN","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2023-06-01","conditions":"Epilepsy, Rare Diseases","enrollment":30},{"nctId":"NCT04997954","phase":"PHASE4","title":"EMERALD TRIAL Open Label Extension Study","status":"UNKNOWN","sponsor":"Gold Coast Hospital and Health Service","startDate":"2021-05-17","conditions":"Amyotrophic Lateral Sclerosis, Cannabis, CBD","enrollment":7},{"nctId":"NCT02607904","phase":"PHASE2","title":"An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-12-15","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02607891","phase":"PHASE2","title":"A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-11-09","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT05574049","phase":"EARLY_PHASE1","title":"Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips","status":"COMPLETED","sponsor":"Medical Life Care Planners, LLC","startDate":"2022-01-04","conditions":"Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia","enrollment":56},{"nctId":"NCT04607603","phase":"PHASE4","title":"Efficacy of Cannabidiol in Knee Osteoarthritis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-10-13","conditions":"Osteo Arthritis Knee, Pain, Joint","enrollment":86},{"nctId":"NCT02565108","phase":"PHASE2","title":"A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-01-20","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT02564952","phase":"PHASE2","title":"An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-03-11","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT02091206","phase":"PHASE2","title":"A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-10-22","conditions":"Epilepsy, Dravet Syndrome","enrollment":34},{"nctId":"NCT03944447","phase":"PHASE2","title":"Outcomes Mandate National Integration With Cannabis as Medicine","status":"UNKNOWN","sponsor":"OMNI Medical Services, LLC","startDate":"2018-12-01","conditions":"Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury","enrollment":200000},{"nctId":"NCT03891264","phase":"PHASE4","title":"Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-11-13","conditions":"Back Pain, Low","enrollment":7},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT05003882","phase":"","title":"Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting","status":"COMPLETED","sponsor":"Radicle Science","startDate":"2021-08-02","conditions":"Pain, Sleep Disturbance, Anxiety","enrollment":3000},{"nctId":"NCT02332655","phase":"PHASE1, PHASE2","title":"Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome","status":"COMPLETED","sponsor":"Anne Comi, MD","startDate":"2014-12","conditions":"Sturge-Weber Syndrome","enrollment":5},{"nctId":"NCT02983695","phase":"PHASE1","title":"Cannabinoid Therapy for Pediatric Epilepsy","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2017-02-02","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT03813095","phase":"PHASE2","title":"Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction","status":"UNKNOWN","sponsor":"Aphios","startDate":"2023-10","conditions":"Addiction, Opioid Dependence, Opioid Withdrawal","enrollment":32},{"nctId":"NCT04732169","phase":"PHASE4","title":"Cannabidiol for Treatment Resistant Depression","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2021-07-01","conditions":"Treatment Resistant Depression","enrollment":""},{"nctId":"NCT04569760","phase":"PHASE3","title":"Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2021-04","conditions":"Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder","enrollment":""},{"nctId":"NCT04601207","phase":"PHASE1","title":"A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population","status":"COMPLETED","sponsor":"New Age Ventures LLC","startDate":"2020-06-19","conditions":"Healthy, Cannabis","enrollment":32},{"nctId":"NCT04609748","phase":"PHASE2","title":"Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint.","status":"UNKNOWN","sponsor":"Pomeranian Medical University Szczecin","startDate":"2021-01-27","conditions":"Temporomandibular Joint Disorders, Temporomandibular Joint Dysfunction Syndrome, Temporomandibular Joint Pain","enrollment":30},{"nctId":"NCT03985995","phase":"NA","title":"Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-09-16","conditions":"Pain Sensation, Hyperalgesia, Allodynia","enrollment":20},{"nctId":"NCT03164512","phase":"PHASE1","title":"The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-06-01","conditions":"Cannabidiol Pharmacokinetics","enrollment":19},{"nctId":"NCT01844687","phase":"PHASE2","title":"Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2013-05","conditions":"Smoking, Marijuana","enrollment":50},{"nctId":"NCT03675971","phase":"PHASE2, PHASE3","title":"COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-05-01","conditions":"Arthroplasty, Replacement, Knee","enrollment":220},{"nctId":"NCT02902081","phase":"NA","title":"Cannabidiol and Emotional Stimuli","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-02","conditions":"Drug Addiction","enrollment":38},{"nctId":"NCT03246113","phase":"PHASE1","title":"Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2018-03-19","conditions":"Glioblastoma","enrollment":1},{"nctId":"NCT01562314","phase":"PHASE2","title":"A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)","status":"COMPLETED","sponsor":"GW Research Ltd","startDate":"2012-05-09","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT02392780","phase":"PHASE2","title":"Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease","status":"UNKNOWN","sponsor":"moshe yeshurun","startDate":"2015-04","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT01596075","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2012-07","conditions":"Graft Versus Host Disease","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cannabidiol Oral Product","genericName":"Cannabidiol Oral Product","companyName":"University of Connecticut","companyId":"university-of-connecticut","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cannabidiol (CBD) is a non-intoxicating cannabinoid that modulates multiple molecular targets including serotonin receptors, TRPV1 channels, and endocannabinoid signaling to produce anti-inflammatory, anxiolytic, and anticonvulsant effects. Used for Seizures associated with Lennox-Gastaut syndrome, Seizures associated with Dravet syndrome, Seizures associated with tuberous sclerosis complex.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}